We are live on ! Find out more
ACM

ADAR1 Capital Management Portfolio holdings

AUM $2.19B
1-Year Est. Return 374.99%
This Fund
S&P 500
This Quarter Est. Return
+8.25%
1 Year Est. Return
+374.99%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$1.7B
AUM Growth
+$337M
Cap. Flow
+$308M
Cap. Flow %
18.12%
Top 10 Hldgs %
39.64%
Holding
351
New
78
Increased
102
Reduced
60
Closed
41

Top Buys

Rank Stock Value
1
BEAM icon
Beam Therapeutics
BEAM
+$40.1M
2
CRNX icon
Crinetics Pharmaceuticals
CRNX
+$37.1M
3
DNLI icon
Denali Therapeutics
DNLI
+$36.2M
4
INSP icon
Inspire Medical Systems
INSP
+$27.3M
5
VIR icon
Vir Biotechnology
VIR
+$21.9M

Top Sells

Rank Stock Value
1
RNAM
Avidity Biosciences
RNAM
+$39.4M
2
RAPT
RAPT Therapeutics
RAPT
+$17.3M
3
CDTX
Cidara Therapeutics
CDTX
+$13.2M
4
FULC icon
Fulcrum Therapeutics
FULC
+$10.4M
5
ABUS icon
Arbutus Biopharma
ABUS
+$9.98M

Sector Composition

Rank Sector Weight
1 Healthcare 88.42%
2 Miscellaneous 9.68%
3 Financials 1.51%
4 Technology 0.08%
5 Industrials 0.08%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
OLMA icon
326
Olema Pharmaceuticals
OLMA
$899M
– –
-81,399
Closed -$2.03M
OMER icon
327
Omeros
OMER
$1.35B
– –
-25,000
Closed -$429K
OMER icon
328
PUT
Omeros
OMER
$1.35B
– –
-75,000
Closed -$1.29M
OTLK icon
329
PUT
Outlook Therapeutics
OTLK
$156M
– –
-100,000
Closed -$158K
PLYM
330
DELISTED
Plymouth Industrial REIT
PLYM
– –
-41,065
Closed -$899K
QNRX
331
Quoin Pharmaceuticals
QNRX
$12.3M
– –
-58,230
Closed -$840K
RAPT
332
DELISTED
RAPT Therapeutics
RAPT
– –
-509,679
Closed -$17.3M
RNAM
333
DELISTED
Avidity Biosciences
RNAM
– –
-546,534
Closed -$39.4M
SABS icon
334
SAB Biotherapeutics
SABS
$345M
– –
-26,344
Closed -$98.5K
SPRO icon
335
Spero Therapeutics
SPRO
$69.9M
– –
-113,839
Closed -$265K
URGN icon
336
CALL
UroGen Pharma
URGN
$2.13B
– –
-40,000
Closed -$937K
UTHR icon
337
United Therapeutics
UTHR
$22.1B
– –
-1,900
Closed -$926K
VTGN icon
338
PUT
VistaGen Therapeutics
VTGN
$11.2M
– –
-120,000
Closed -$79.4K
VTYX
339
DELISTED
Ventyx Biosciences
VTYX
– –
-81,600
Closed -$737K
DAY
340
DELISTED
Dayforce
DAY
– –
-5,000
Closed -$346K
BBOT
341
BridgeBio Oncology
BBOT
$701M
– –
-226,248
Closed -$2.83M
ZONE
342
CleanCore Solutions
ZONE
$33.8M
– –
-521,980
Closed -$136K
AAM
343
CALL
DELISTED
AA Mission Acquisition Corp
AAM
– –
-405,089
Closed -$4.32M
AAM
344
DELISTED
AA Mission Acquisition Corp
AAM
– –
-578,359
Closed -$6.17M
IVF
345
INVO Fertility Inc
IVF
$2.51M
– –
-5,344
Closed -$20.1K
GRCE
346
Grace Therapeutics
GRCE
$44.6M
– –
-641,988
Closed -$2.22M
CCCX
347
DELISTED
Churchill Capital Corp X
CCCX
– –
-64,887
Closed -$1.01M
10 11 12 13
14

Similar funds

GAMH
Greenwoods Asset Management (HK) Hong Kong $2.19B AUM 50.16% 1-Year Est. Return
RCAG
Rehmann Capital Advisory Group Lansing, Michigan $2.18B AUM 23.73% 1-Year Est. Return
AF
Advisornet Financial Minnetonka, Minnesota $2.19B AUM 21.28% 1-Year Est. Return
AWM
Angeles Wealth Management Santa Monica, California $2.19B AUM 23.13% 1-Year Est. Return
TCM
Traynor Capital Management Malvern, Pennsylvania $2.18B AUM 62.36% 1-Year Est. Return
WRBC
W.R. Berkley Corp Greenwich, Connecticut $2.18B AUM 13.58% 1-Year Est. Return
IAN
Integrated Advisors Network Dallas, Texas $2.18B AUM 30.3% 1-Year Est. Return
BOI
Bank of Italy Rome, Italy $2.2B AUM 1.53% 1-Year Est. Return

ADAR1 Capital Management's Q1 2026 Portfolio in Review

As of Q1 2026, ADAR1 Capital Management held 351 positions worth $1.7B, up 25% from $1.36B the previous quarter. Its ten largest holdings account for 40% of the portfolio.

ADAR1 Capital Management deployed $308M of net new capital in Q1 2026, opening 78 new positions and adding to 102 existing holdings. Its largest new stake was Beam Therapeutics: 1,446,375 shares worth $34.5M.

By sector, the portfolio is most concentrated in Healthcare at 88% of assets, down from 89% a quarter earlier, followed by Miscellaneous and Financials.

On the sell side, the largest reduction was Fulcrum Therapeutics, an estimated $10.4M trimmed.

  • ADAR1 Capital Management's largest Q1 2026 buy was Beam Therapeutics: 1,446,375 shares worth $34.5M.
  • ADAR1 Capital Management added most to Crinetics Pharmaceuticals in Q1 2026, an estimated $37.1M increase.
  • ADAR1 Capital Management's biggest Q1 2026 reduction was Fulcrum Therapeutics, cutting an estimated $10.4M.
  • ADAR1 Capital Management fully exited Avidity Biosciences in Q1 2026, selling an estimated $39.4M.
  • ADAR1 Capital Management's ten largest holdings make up 40% of its $1.7B portfolio in Q1 2026.
  • ADAR1 Capital Management opened 78 new positions and closed 41 in Q1 2026.
  • ADAR1 Capital Management's portfolio value rose 25% quarter-over-quarter to $1.7B.

Based on ADAR1 Capital Management's 13F filing for Q1 2026, filed 18 May 2026.